A Cost-Effectiveness Analysis of LDV/SOF+RBV for 12 Weeks vs. LDV/SOF 24 Weeks vs. SOF+SMV 24 Weeks in CHC Gt1 TE Cirrhotic Patients

被引：0
|
作者：
Ahmed, Aijaz
Dieterich, Douglas T.
Park, Haesuk
Saab, Sammy
Gordon, Stuart C.
Younossi, Zobair M.
机构：
来源：
GASTROENTEROLOGY | 2015年 / 148卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
812
引用
收藏
页码：S999 / S999
页数：1
相关论文
共 18 条
  • [1] Effectiveness of 12 or 24 week LDV/SOF and 12 week LDV/SOF plus RBV in treatment-experienced patients with cirrhotic, genotype 1 Hepatitis C: Real-world experience from the TRIO Network
    Curry, Michael P.
    Bacon, Bruce
    Flamm, Steven L.
    Kowdley, Kris V.
    Dieterich, Douglas
    Milligan, Scott
    Tsai, Naoky C. S. C.
    [J]. HEPATOLOGY, 2015, 62 : 755A - 755A
  • [2] EFFECTIVENESS OF 12 OR 24 WEEK LDV/SOF AND 12 WEEK LDV/SOF plus RBV IN TREATMENT-EXPERIENCED PATIENTS WITH CIRRHOTIC, GENOTYPE 1 HEPATITIS C: REAL-WORLD EXPERIENCE FROM THE TRIO NETWORK
    Curry, M.
    Bacon, B.
    Dieterich, D.
    Flamm, S.
    Guest, L.
    Kowdley, K.
    Lee, Y.
    Tsai, N.
    Younossi, Z.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A312 - A313
  • [3] Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 HCV Infection
    Pol, S.
    Aghemo, A.
    Lin, L.
    Hyland, R.
    Yun, C.
    Spellman, J.
    Natha, M.
    Brainard, D.
    McHutchison, J.
    Bourliere, M.
    Peck-Radosavljevic, M.
    Michael, M.
    Colombo, M.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 262 - 262
  • [4] Real World Effectiveness of 8 vs 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) in Blacks with HCV: A Comparative Analysis of Clinical Trials with Real World Cohorts
    Wilson, Eleanor
    Davitkov, Perica
    Kwo, Paul Y.
    Kattakuzhy, Sarah
    Qureshi, Kamran
    Sundaram, Vinay
    Naik, Sarjita
    Williams, Laurie A.
    Wolf, John
    Llewellyn, Joseph
    Osinusi, Anu O.
    Brainard, Diana M.
    Gordon, Stuart C.
    Backus, Lisa I.
    Kowdley, Kris V.
    [J]. HEPATOLOGY, 2017, 66 : 608A - 608A
  • [5] Ledipasvir/Sofosbuvir plus Ribavirin (LDV/SOF+RBV) for 12 Weeks in Decompensated HCV Genotype 1 Patients: SOLAR-1 and-2 Studies Compared to a Real-World Dataset
    Charlton, Michael R.
    Cheung, Michelle C.
    Manns, Michael P.
    Sajed, Nika
    Troke, Philip
    Spellman, James G.
    Copans, Amanda
    Arterburn, Sarah
    Brainard, Diana M.
    Irving, William
    Foster, Graham R.
    [J]. HEPATOLOGY, 2016, 64 : 489A - 490A
  • [6] Retreatment of HCV GT-1 in Patients Who Failed Previous Short Course Combination DAA Therapy With 12 Weeks of LDV/SOF is Highly Effective
    Wilson, Eleanor
    Kattakuzhy, Sarah
    Tang, Lydia
    Sims, Zayani
    McIaughlin, Mary
    Price, Angie
    Mo, Hongmei
    Osinusi, Anu
    Masur, Henry
    Kohli, Anita
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 71 : 77 - 77
  • [7] Ledipasvir/Sofosbuvir plus Ribavirin (LDV/SOF+RBV) for 12 Weeks in Decompensated HCV Genotype 1 Patients: SOLAR-1 and SOLAR-2 Studies Compared to a Real-world Dataset
    Charlton, M.
    Cheung, M. C. M.
    Manns, M.
    Sajed, N.
    Troke, P. J. F.
    Spellman, J.
    Copans, A.
    Arterburn, S.
    Brainard, D. M.
    Irving, W. L.
    Foster, G. R.
    [J]. TRANSPLANTATION, 2017, 101 (05) : 92 - 92
  • [8] Effectiveness of 8 vs. 12 week ledipasvir-sofosbuvir (LDV/SOF) in black, treatment naive patients with non-cirrhotic, genotype 1 HCV and baseline viral load
    Curry, M.
    Bacon, B.
    Flamm, S.
    Landen, A.
    Milligan, S.
    Tsai, N.
    Younossi, Z.
    Afdhal, N.
    [J]. JOURNAL OF HEPATOLOGY, 2018, 68 : S271 - S272
  • [9] REAL-WORD EFFECTIVENESS OF 8, 12 AND 24 WEEKS LEDIPASVIR (LDV)/SOFOSBUVIR (SOF)-BASED THERAPY FOR HEPATITIS C VIRUS (HCV) GENOTYPE 1: ANALYSIS IN A LARGE INTEGRATED HEALTH CARE SYSTEM
    Lai, J.
    Witt, M.
    Witt, D.
    [J]. JOURNAL OF HEPATOLOGY, 2016, 64 : S778 - S778
  • [10] Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy
    Umberto Restelli
    Alfredo Alberti
    Adriano Lazzarin
    Marzia Bonfanti
    Carmela Nappi
    Davide Croce
    [J]. The European Journal of Health Economics, 2018, 19 : 37 - 44
12